The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
Open accessAbstract
Summary Ponatinib is the only currently approved tyrosine kinase inhibitor (TKI) that suppresses all BCR-ABL1 single mutants in Philadelphia chromosome-positive (Ph+) leukemia, including the recalcitrant BCR-ABL1T315I mutant. However, emergence of compound mutations in a BCR-ABL1 allele may confer ponatinib resistance. We found that clinically reported BCR-ABL1 compound mutants center on 12 key positions and confer varying resistance to imatinib, nilotinib, dasatinib, ponatinib, rebastinib and bosutinib. T315I-inclusive compound mutants confer high-level resistance to TKIs, including ponatinib. In vitro resistance profiling was predictive of treatment outcomes in Ph+ leukemia patients. Structural explanations for compound mutation-based resistance were obtained through molecular dynamics simulations. Our findings demonstrate that BCR-ABL1 compound mutants confer different levels of TKI resistance, necessitating rational treatment selection to optimize clinical outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
Self-citationClinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Self-citationCharacterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492
Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL
Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O'Brien, S., Wassmann, B., Tanaka, C., Manley, P., Rae, P., Mietlowski, W., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055104 · Cited by 1,344
Self-citationO'Hare, T., Shakespeare, W. C., Zhu, X., Eide, C. A., Rivera, V. M., Wang, F., Adrian, L. T., Zhou, T., Huang, W.-S., Xu, Q., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.028 · Cited by 1,259
Self-citationA Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
Cortes, J. E., Kim, D.-W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., Nicolini, F. E., Apperley, J. F., Khoury, H. J., Talpaz, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306494 · Cited by 1,142
Self-citationMolecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
Hochhaus, A., Kreil, S., Corbin, A., La Rosée, P., Müller, M., Lahaye, T., Hanfstein, B., Schoch, C., Cross, N., Berger, U., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402741 · Cited by 906
Self-citationPonatinib in Refractory Philadelphia Chromosome–Positive Leukemias
Cortes, J. E., Kantarjian, H., Shah, N. P., Bixby, D., Mauro, M. J., Flinn, I., O'Hare, T., Hu, S., Narasimhan, N. I., Rivera, V. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205127 · Cited by 769
Self-citationTokarski, J. S., Newitt, J. A., Chang, C. Y. J., Cheng, J. D., Wittekind, M., Kiefer, S. E., Kish, K., Lee, F. Y. F., Borzillerri, R., Lombardo, L. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4187 · Cited by 700
Donato, N. J., Wu, J. Y., Stapley, J., Gallick, G., Lin, H., Arlinghaus, R., & Talpaz, M. (2003) · Blood · doi:10.1182/blood.v101.2.690 · Cited by 663
Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia
Apperley, J. F. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70342-x · Cited by 643
Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL
Azam, M., Latek, R. R., & Daley, G. Q. (2003) · Cell · doi:10.1016/s0092-8674(03)00190-9 · Cited by 613
Peng, B., Hayes, M., Resta, D., Racine-Poon, A., Druker, B. J., Talpaz, M., Sawyers, C. L., Rosamilia, M., Ford, J., Lloyd, P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.050 · Cited by 472
Self-citationCortes, J. E., Kantarjian, H. M., Brümmendorf, T. H., Kim, D.-W., Turkina, A. G., Shen, Z.-X., Pasquini, R., Khoury, H. J., Arkin, S., Volkert, A., et al. (2011) · Blood · doi:10.1182/blood-2011-05-355594 · Cited by 463
Self-citationShah, N. P., Skaggs, B. J., Branford, S., Hughes, T. P., Nicoll, J. M., Paquette, R. L., & Sawyers, C. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30890 · Cited by 418
Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1
Awad, M. M., Katayama, R., McTigue, M., Liu, W., Deng, Y.-L., Brooun, A., Friboulet, L., Huang, D., Falk, M. D., Timofeevski, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215530 · Cited by 416
Activation of tyrosine kinases by mutation of the gatekeeper threonine
Azam, M., Seeliger, M. A., Gray, N. S., Kuriyan, J., & Daley, G. Q. (2008) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1486 · Cited by 411
Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants
Redaelli, S., Piazza, R., Rostagno, R., Magistroni, V., Perini, P., Marega, M., Gambacorti-Passerini, C., & Boschelli, F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8853 · Cited by 399
Bradeen, H. A., Eide, C. A., O'Hare, T., Johnson, K. J., Willis, S. G., Lee, F. Y., Druker, B. J., & Deininger, M. W. (2006) · Blood · doi:10.1182/blood-2006-02-004580 · Cited by 393
Self-citationBurgess, M. R., Skaggs, B. J., Shah, N. P., Lee, F. Y., & Sawyers, C. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409770102 · Cited by 313
Pushing the limits of targeted therapy in chronic myeloid leukaemia
O'Hare, T., Zabriskie, M. S., Eiring, A. M., & Deininger, M. W. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3317 · Cited by 304
Self-citationZhou, T., Commodore, L., Huang, W., Wang, Y., Thomas, M., Keats, J., Xu, Q., Rivera, V. M., Shakespeare, W. C., Clackson, T., et al. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2010.01054.x · Cited by 287
Dai, Y., Rahmani, M., Corey, S. J., Dent, P., & Grant, S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402290200 · Cited by 239
Khorashad, J. S., Kelley, T. W., Szankasi, P., Mason, C. C., Soverini, S., Adrian, L. T., Eide, C. A., Zabriskie, M. S., Lange, T., Estrada, J. C., et al. (2013) · Blood · doi:10.1182/blood-2012-05-431379 · Cited by 222
Self-citationChan, W. W., Wise, S. C., Kaufman, M. D., Ahn, Y. M., Ensinger, C. L., Haack, T., Hood, M. M., Jones, J., Lord, J. W., Lu, W. P., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.003 · Cited by 208
Griswold, I. J., MacPartlin, M., Bumm, T., Goss, V. L., O'Hare, T., Lee, K. A., Corbin, A. S., Stoffregen, E. P., Smith, C., Johnson, K., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.02202-05 · Cited by 200
Self-citationSoverini, S., Gnani, A., Colarossi, S., Castagnetti, F., Abruzzese, E., Paolini, S., Merante, S., Orlandi, E., de Matteis, S., Gozzini, A., et al. (2009) · Blood · doi:10.1182/blood-2009-01-197186 · Cited by 175
Self-citationSoverini, S., De Benedittis, C., Machova Polakova, K., Brouckova, A., Horner, D., Iacono, M., Castagnetti, F., Gugliotta, G., Palandri, F., Papayannidis, C., et al. (2013) · Blood · doi:10.1182/blood-2013-03-487728 · Cited by 163
Self-citationAnalysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571
Corbin, A. S., Buchdunger, E., Pascal, F., & Druker, B. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111525200 · Cited by 162
Self-citationManley, P. W., Cowan-Jacob, S. W., & Mestan, J. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.07.040 · Cited by 160
Khorashad, J. S., Anand, M., Marin, D., Saunders, S., Al-Jabary, T., Iqbal, A., Margerison, S., Melo, J. V., Goldman, J. M., Apperley, J. F., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404137 · Cited by 149
Self-citationPhosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants
Skaggs, B. J., Gorre, M. E., Ryvkin, A., Burgess, M. R., Xie, Y., Han, Y., Komisopoulou, E., Brown, L. M., Loo, J. A., Landaw, E. M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609239103 · Cited by 142
Ray, A., Cowan‐Jacob, S. W., Manley, P. W., Mestan, J., & Griffin, J. D. (2007) · Blood · doi:10.1182/blood-2006-01-015347 · Cited by 128
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD
Smith, C. C., Lasater, E. A., Zhu, X., Lin, K. C., Stewart, W. K., Damon, L. E., Salerno, S. N., & Shah, N. P. (2013) · Blood · doi:10.1182/blood-2012-07-442871 · Cited by 127
Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins
Davare, M. A., Saborowski, A. L., Eide, C. A., Tognon, C. E., Smith, R. L., Elferich, J., Agarwal, A., Tyner, J. W., Shinde, U. P., Lowe, S. W., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319583110 · Cited by 122
Self-citationEide, C. A., Adrian, L. T., Tyner, J. W., Partlin, M. M., Anderson, D. J., Wise, S., Smith, B. D., Petillo, P. A., Flynn, D. L., Deininger, M. W., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3224 · Cited by 115
Self-citationHochhaus, A., Saglio, G. N., Larson, R. A., Kim, D., Étienne, G., Rosti, G., Souza, C. A. D., Kurokawa, M., Kalaycio, M. E., Hoenekopp, A., et al. (2013) · Blood · doi:10.1182/blood-2012-04-423418 · Cited by 98
Self-citationKhorashad, J. S., Milojković, D., Mehta, P., Anand, M., Ghorashian, S., Reid, A. G., Melo, V. D., Babb, A., de Lavallade, H., Olavarría, E., et al. (2007) · Blood · doi:10.1182/blood-2007-06-096396 · Cited by 87
Self-citationGibbons, D. L., Pricl, S., Posocco, P., Laurini, E., Fermeglia, M., Sun, H., Talpaz, M., Donato, N. J., & Quintás‐Cardama, A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321173111 · Cited by 78
Kastner, R., Zopf, A., Preuner, S., Pröll, J., Niklas, N., Foskett, P., Valent, P., Lion, T., & Gabriel, C. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.11.030 · Cited by 39
Ponatinib Is a Pan-BCR-ABL Kinase Inhibitor: MD Simulations and SIE Study
Tanneeru, K., & Guruprasad, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078556 · Cited by 33
FDA halts then allows sales of Ariad's leukemia medication
Senior, M. (2014) · Nature Biotechnology · doi:10.1038/nbt0114-9a · Cited by 20
Kim, D., Kim, D. J., Cho, B., Goh, H., Kim, S.-H., Kim, W., Js, L., Kweon, I., Park, S.-H., Yoon, J. H., et al. (2009) · Leukemia Research · doi:10.1016/j.leukres.2008.12.017 · Cited by 19
Stagno, F., Stella, S., Berretta, S., Massimino, M., Antolino, A., Giustolisi, R., Messina, A., Raimondo, F. D., & Vigneri, P. G. (2007) · Leukemia Research · doi:10.1016/j.leukres.2007.08.008 · Cited by 13
Kim, W., Kim, D., Kim, D., Kweon, I., Kim, S., Goh, H., Park, S.-H., & Lee, J. E. (2009) · Hematological Oncology · doi:10.1002/hon.918 · Cited by 11
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Response and Resistance to BCR-ABL1-Targeted Therapies
Braun, T. P., Eide, C. A., & Druker, B. J. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.006 · Cited by 483
Self-citationMartinelli, G., Boissel, N., Chevallier, P., Ottmann, O., Gökbuget, N., Topp, M. S., Fielding, A. K., Rambaldi, A., Ritchie, E. K., Papayannidis, C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.3531 · Cited by 445
Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy
Rossari, F., Minutolo, F., & Orciuolo, E. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0624-2 · Cited by 371
Yoda, S., Lin, J. J., Lawrence, M. S., Burke, B. J., Friboulet, L., Langenbucher, A., Dardaei, L., Prutisto-Chang, K., Dagogo-Jack, I., Timofeevski, S., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1256 · Cited by 322
Metadata
- Authors
- Zabriskie, M. S., Eide, C. A., Tantravahi, S. K., Vellore, N. A., Estrada, J., Nicolini, F. E., Khoury, H. J., Larson, R. A., Konopleva, M., Cortes, J. E., Kantarjian, H., Jabbour, E. J., Kornblau, S. M., Lipton, J. H., Rea, D., Stenke, L., Barbany, G., Lange, T., Hernández-Boluda, J.-C., Ossenkoppele, G. J., Press, R. D., Chuah, C., Goldberg, S. L., Wetzler, M., Mahon, F.-X., Etienne, G., Baccarani, M., Soverini, S., Rosti, G., Rousselot, P., Friedman, R., Deininger, M., Reynolds, K. R., Heaton, W. L., Eiring, A. M., Pomicter, A. D., Khorashad, J. S., Kelley, T. W., Baron, R., Druker, B. J., Deininger, M. W., & O’Hare, T.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2014-09
- Volume
- 26
- Issue
- 3
- Pages
- 428-442
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2140351909
- Cited by
- 363
- References
- 47
- FWCI
- 24.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.